Label (71610 0931 30)
Pregabalin Capsule
Product Images NDC 71610-931
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-931). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Aphena (Aphena)
Chemical Structure (Pregabalin 01)
Figure 1 (Pregabalin 02)
Figure 2 (Pregabalin 03)
Figure 3 (Pregabalin 04)
Figure 4 (Pregabalin 05)
This data shows the percentage of patients that experienced improvement in pain based on the administration of Pregabalin at different doses compared to a placebo, over a period of days. The chart displays the impact on pain levels over time.*
Figure 5 (Pregabalin 06)
This text provides information about the percentage of patients who improved using different dosages of Pregabalin and a placebo. It mentions Pregabalin dosages of 100mg and 80mg three times a day, as well as a placebo. The chart seems to show the percentage of improvement in pain from baseline for each group.*
Figure 6 (Pregabalin 07)
Figure 7 (Pregabalin 08)
Figure 8 (Pregabalin 09)
This text provides information on responder rates for different treatments, including placebo and doses of 2.5 mg/kg/day and 10 mg/kg/day. The responder rate (%) for each treatment is given.*
Figure 9 (Pregabalin 10)
Percent of Patients Improved: 100
This text provides information about the percent improvement in pain from baseline for different doses of the medication Preguizsin. The values mentioned are for Preguizsin L0 car dose, Pregaoain 4807 car dose, and Pregassin A0mg ea dose. Additionally, there is reference to a placebo group. It appears to be a summary of the improvement in pain experienced by patients after taking these medications compared to their baseline pain levels.*
Figure 10 (Pregabalin 11)
Figure 11 (Pregabalin 12)
The provided information shows the percentage of subjects who improved from baseline to week 12 with Pregabalin treatment. The data indicates that between 90% and 100% of subjects experienced improvement during the specified time period.*
Figure 12 (Pregabalin 13)
Not available.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
